PE859 - CAS 1402727-29-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Microtubule/Tubulin | Tau
PE859 is a potent dual inhibitor of tau and Aβ aggregation with IC50 values of 0.66 and 1.2 μM, respectively.
Brife Description:
A potent dual inhibitor of tau and Aβ aggregation with IC50 values of 0.66 and 1.2 μM, respectively
6-[(E)-2-[5-[(E)-2-[2-methoxy-4-(pyridin-2-ylmethoxy)phenyl]ethenyl]-1H-pyrazol-3-yl]ethenyl]-1H-indole; PE859; PE-859; PE 859
DMSO: ≥ 30 mg/mL
Store in a cool and dry place (or refer to the Certificate of Analysis).
Boiling Point:
747.7±60.0 ℃ at 760 Torr
1.312±0.06 g/cm3
Canonical SMILES:
1.PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.
Okuda M;Hijikuro I;Fujita Y;Wu X;Nakayama S;Sakata Y;Noguchi Y;Ogo M;Akasofu S;Ito Y;Soeda Y;Tsuchiya N;Tanaka N;Takahashi T;Sugimoto H PLoS One. 2015 Feb 6;10(2):e0117511. doi: 10.1371/journal.pone.0117511. eCollection 2015.
In tauopathies, a neural microtubule-associated protein tau (MAPT) is abnormally aggregated and forms neurofibrillary tangle. Therefore, inhibition of the tau aggregation is one of the key approaches for the treatment of these diseases. Here, we have identified a novel tau aggregation inhibitor, PE859. An oral administration of PE859 resulted in the significant reduction of sarkosyl-insoluble aggregated tau along with the prevention of onset and progression of the motor dysfunction in JNPL3 P301L-mutated human tau transgenic mice. These results suggest that PE859 is useful for the treatment of tauopathies.
2.Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors.
Okuda M;Hijikuro I;Fujita Y;Teruya T;Kawakami H;Takahashi T;Sugimoto H Bioorg Med Chem Lett. 2016 Oct 15;26(20):5024-5028. doi: 10.1016/j.bmcl.2016.08.092. Epub 2016 Aug 31.
Alzheimer's disease (AD) is the most common form of dementia. In an AD patient's brain, senile plaques and neurofibrillary tangles, the abnormal aggregates of amyloid β (Aβ) peptide and tau protein, are observed as the two major hallmarks of this disease. To develop a new drug for treatment of AD, we have designed and synthesized a series of curcumin derivatives and evaluated their inhibitory activities against both tau and Aβ aggregation. In this study, we describe the development of the more potent aggregation inhibitor 3-[(1E)-2-(1H-indol-6-yl)ethenyl]-5-[(1E)-2-[2-methoxy-4-(2-pyridylmethoxy) phenyl] ethenyl]-1H-pyrazole (compound 4, PE859). This compound has a better pharmacokinetic profile and pharmacological efficacy in vivo than curcumin, making it suitable as a drug for AD.
3.PE859, A Novel Curcumin Derivative, Inhibits Amyloid-β and Tau Aggregation, and Ameliorates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8.
Okuda M;Fujita Y;Hijikuro I;Wada M;Uemura T;Kobayashi Y;Waku T;Tanaka N;Nishimoto T;Izumi Y;Kume T;Akaike A;Takahashi T;Sugimoto H J Alzheimers Dis. 2017;59(1):313-328. doi: 10.3233/JAD-161017.
Aggregation of amyloid-β (Aβ) and tau plays a crucial role in the onset and progression of Alzheimer's disease (AD). Therefore, the inhibition of Aβ and tau aggregation may represent a potential therapeutic target for AD. Herein, we designed and synthesized both Aβ and tau dual aggregation inhibitors based on the structure of curcumin and developed the novel curcumin derivative PE859. In this study, we investigated the inhibitory activity of PE859 on Aβ aggregationin vitro and the therapeutic effects of PE859 on cognitive dysfunction via dual inhibition of Aβ and tau aggregation in vivo. PE859 inhibited Aβ aggregation in vitro and protected cultured cells from Aβ-induced cytotoxicity. Furthermore, PE859 ameliorated cognitive dysfunction and reduced the amount of aggregated Aβ and tau in brains of senescence-accelerated mouse prone 8 (SAMP8). These results warrant consideration of PE859 as a candidate drug for AD.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Microtubule/Tubulin Products

CAS 14255-87-9 Parbendazole

(CAS: 14255-87-9)

Parbendazole, a benzimidazole carbamat used as an antinematodal agent, is a potent inhibitor of microtubule assembly and functions.


ACI-35 is a liposome-based vaccine designed to stimulate a patient’s immune system to produce antibodies against the misfolded and phosphorylated pathogenic for...

CAS 74588-78-6 D-64131

(CAS: 74588-78-6)

D-64131, under the IUPAC name (5-methoxy-1H-indol-2-yl)-phenylmethanone, is a 2-aroylindole derivatives that inhibits tubulin polymerization. In vitro: Inhibits...

CAS 253128-41-5 Eribulin

(CAS: 253128-41-5)

Eribulin suppressed centromere dynamics at concentrations that arrest mitosis. At 60 nmol/L eribulin (2 x mitotic IC(50)), the relaxation rate was suppressed 21...

CAS 189453-10-9 Epothilone D

Epothilone D
(CAS: 189453-10-9)

Epothilone D is a natural polyketide compound isolated from the myxobacterium Sorangium cellulosum. Also known as desoxyepothilone B, epothilone D binds to tubu...

CAS 442-51-3 Harmine

(CAS: 442-51-3)

Harmine induces apoptosis and inhibits proliferation, migration and invasion of human gastric cancer cells, which may be mediated by down-regulation of COX-2 ex...

Dolastatin 10 trifluoroacetate

Dolastatin 10 trifluoroacetate inhibits tubulin polymerization and induces tubulin aggregation in vitro.

CAS 41179-33-3 CMPD-1

(CAS: 41179-33-3)

CMPD-1, also called MK2a Inhibitor, inhibits tubulin polymerisation. It inhibit p38α-mediated MK2a phosphorylation (apparent Ki = 330 nM).

Chemical Structure

CAS 1402727-29-0 PE859

Quick Inquiry

Verification code

Featured Items